

[Home](#) > [Select Nirsevimab \(Beyfortus\) Products](#)

Select Nirsevimab (Beyfortus) Products

This form must be completed when requesting Beyfortus™ (nirsevimab) for eligible infants and children.

Up to five individuals can be added to the form.

Refer to the:

- [Australian Immunisation Handbook](#) for **dosage recommendations**
- [Eligibility for Abrysvo® and nirsevimab \(Beyfortus™\)](#) for **eligibility information**
- [Clinical decision aid for nirsevimab \(Beyfortus™\) in newborn infants](#)
- [Clinical decision aid for nirsevimab \(Beyfortus™\) in infants and children up to 24 months of age who remain at risk of severe RSV disease.](#)

Any next day or urgent delivery for the Nirsevimab vaccine program will not be approved.

Please consider the below delivery times as a guide when placing your order and planning appointments:

- Metropolitan Sydney: 2 business days
- Regional: 3-5 business days
- Remote: 4-6 business days

Order information:

ADD TO CART

NIRSEVIMAB

TOTAL DOSES REQUIRED

Beyfortus™ (Nirsevimab) 100mg vial

Beyfortus™ (Nirsevimab) 50mg vial

Delivery Date required:

▼ /

▼ /

▼

Order note (optional):

Patient 1 details:

Name

(de-identified 2x2 e.g. John Smith = JoSm):

DOB:

▼ /

▼ /

▼

Age:

Weight:

Did the mother receive maternal RSV vaccination Abrysvo® 2 weeks before delivery?

☐ Yes ☐ No

Infants born less than 2 weeks before administration of Abrysvo are not considered protected by maternal vaccination.

Eligibility to receive nirsevimab (tick applicable option)

☒ **Infants born on or after 1 January 2025 who are:**

Not protected by maternal RSV vaccination ☐ Yes ☐ No

Born with risk conditions for severe RSV disease, as per the [Australian Immunisation Handbook](#), regardless of maternal vaccination status ☐ Yes ☐ No

☒ **NSW RSV Vulnerable Babies Program catch-up for infants born from 1 October 2024 to 31 December 2024 who meet the following eligibility criteria and are not protected through maternal vaccination and did not receive nirsevimab at birth:**

All premature infants born less than 37 weeks gestation ☐ Yes ☐ No

All Aboriginal and Torres Strait Islander infants ☐ Yes ☐ No

Chronic lung disease (requiring ongoing home oxygen or respiratory support) ☐ Yes ☐ No

Ongoing haemodynamically significant congenital heart disease ☐ Yes ☐ No

*Significant immunosuppression, such as from solid organ transplant, haematopoietic stem cell transplant, or primary immune deficiencies such as severe combined immunodeficiency (SCID) ☐ Yes ☐ No

*Trisomy 21 or another genetic condition that increases the risk of severe RSV disease ☐ Yes ☐ No

*Cystic fibrosis with severe lung disease or weight for length < 10th percentile ☐ Yes ☐ No

*Neurological conditions that impair respiratory function ☐ Yes ☐ No

Has a specialist paediatrician or other specialist been consulted for the conditions marked with an *? ☐ Yes ☐ No

Patient 2 details:

Name
(de-identified 2x2 e.g. John Smith = JoSm):

DOB: / /

Age:

Weight:

Did the mother receive maternal RSV vaccination Abrysvo® 2 weeks before delivery? ☐ Yes ☐ No

Infants born less than 2 weeks before administration of Abrysvo are not considered protected by maternal vaccination.

Eligibility to receive nirsevimab (tick applicable option)

ADD PATIENT

ADD TO CART